Topic:

M&A

Latest Headlines

Latest Headlines

3D Systems buys surgical virtual reality player for $120M, falls 11% on earnings miss

3D Systems missed Wall Street earnings expectations because of product delays. The newly disclosed acquisition of Simbionix by 3D Systems for $120 million in cash went largely unnoticed as a consequence; the deal is designed to add 3D virtual reality surgical simulation capabilities to the 3D printer.

Device share of healthcare venture capital funding hits decade low

While medical device venture activity may have picked up this year, the comparison point in 2013 was abysmally low. In addition, Series A device investment was still shrinking. That's according to a new report from Silicon Valley Bank. These trends are pushing the sector to be more reliant on angel investors, which are becoming more accessible with the advent of crowdfunding, and corporate VCs, who are stealthy but increasingly active.

Eyeing consumer health, Meda nabs Italy's Rottapharm in long-sought $3B deal

Meda has staunchly refused every takeover bid that's come its way. But that doesn't mean the Swedish drugmaker isn't interested in M&A. It just prefers to be the buyer. Meda says it's agreed to buy the family-owned Italian drugmaker Rottapharm for about 21.2 billion kronor ($3.1 billion), with an eye on its consumer health offerings.

Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall's lung meds

AstraZeneca has agreed to pay $875 million up front--and up to $2.2 billion total, with milestones--for Almirall's respiratory portfolio. The deal brings a couple of marketed drugs, and a list of pipeline meds that includes a combo drug Almirall is developing with U.S.-based Forest Laboratories.

Will he or won't he? Pfizer CEO scouts big deals, but 'silent' on AstraZeneca rebid

No news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEO Ian Read's next buyout move was disappointed after Tuesday's second-quarter earnings call with analysts.

A $635M win-win deal boosts Pfizer in vaccines, slims Baxter for spinoff

Looks like Pfizer's finally getting the vaccines expansion it's been hankering for. The company agreed to pick up Baxter's marketed vaccines portfolio for $635 million, building up its own business as the Illinois healthcare company slims down for a pharma unit spinoff next year.

AstraZeneca bets on respiratory growth with $2.1B Almirall deal

AstraZeneca has signed an agreement to pick up Almirall's respiratory business for up to $2.1 billion, hoping to shoulder its way to the front of a blockbuster market for COPD treatments.

Dental implant player Nobel Biocare is the latest med tech M&A target

Nobel Biocare has confirmed it is in early discussions with potential buyers, after a Bloomberg article reported a rumored sale. The report said the company has hired Goldman Sachs to broker a transaction.

Don't get too excited, investors: GSK has no near-term plans for consumer health spinoff

Let GlaxoSmithKline be clear: It's open to spinning off its consumer healthcare division at some nebulous point in the future. But it's not happening anytime soon.

Medtronic buys surgical tech startup for up to $105M, adds to Covidien strength

With the acquisition of surgical technology company Visualase, Medtronic is further bolstering one of its own fastest growing segments--as well as a large and fast growing group for Covidien. Medtronic expects to complete its $42.9 billion acquisition of Covidien by early 2015.